The phase 3 CALLA trial revealed no indication of benefit with the addition of durvalumab to standard definitive chemoradiation for locally-advanced cervical cancer. In better news, radiation quality was uniformly high across this broad international trial.
Citation(s)
- Mayadev, ASTRO 2022